NRSN NeuroSense Therapeutics Ltd. stock chart & analysis
Conviction 40HealthcareScan · Wed, Nov 4, 2026NeuroSense Therapeutics Ltd. (NRSN) closed at $1.28 on Nov 4, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 17, RS Rating 2, -95.0% from its 52-week high, -91.7% year to date. Sector: Healthcare.
Why NRSN moved
From the StockSetups movers recaps that covered NRSN, newest first. A recap states what was known that day.
- Close+28.3%
No news headlines or recent filings explain the move. The most recent SEC filing is a 6-K (a foreign private issuer's report of significant events) from August 27, which is too old to be today's trigger. With no identifiable catalyst, this appears to be a momentum-driven pop in a thinly traded micro-cap.
Top Stock Movers Today — September 4, 2026: Why IMRN, CDTG, GRNQ, NRSN & GRI Surged →
NRSN technical analysis
Trend
NRSN is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 75.3% below the 50-day ($5.19) and 89.9% below the 200-day ($12.69). ADX(14) at 50 points to a strong, established trend. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 17, in oversold territory. MACD crossed above its signal line 8 sessions ago. A bullish MACD divergence is in place. Its RS Rating of 2 puts its weighted 12-month performance ahead of about 2% of the US market.
Volume and volatility
It trades about $90,565 a day on average. ATR(14) is $0.5135, 40.1% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.30) shows distribution.
Key levels
The chart pattern's support is $2.99 and its resistance $7.46. The 52-week range is $1.10 to $25.40; price is 95.0% below the high and 16.4% above the low. The VWAP anchored at the 52-week high is $11.08, above price.
Performance
NRSN returned -46.0% (1 week), -68.2% (1 month), -88.2% (3 months), -93.3% (6 months), -94.3% (1 year), -91.7% (year to date).
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Listed 2021 · 16 employees
Recent news
- NRSN Downgraded by HC Wainwright & Co. -- Rating Changed to NeutGuruFocus · Mon, Nov 2, 2026
- An ALS drug application target moves back as NeuroSense (NRSN) plans to add trial data.Stock Titan · Mon, Nov 2, 2026
- NeuroSense Therapeutics Ltd. (NRSN) Targets March 2027 Canadian Filing With New NfL DataTradingView · Mon, Nov 2, 2026
- NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL DataYahoo Finance · Mon, Nov 2, 2026
Insider activity
SEC Form 4 transactions in NRSN · open-market 1 buy
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Ben-Noon Alon Chief Executive Officer · Ordinary Shares · 2026-06-16 | Buy | 250K | $200K | 2026-06-16 | 2026-06-17 |
SEC filings
EDGAR filings in NRSN · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.